A patent review of mutant-selective PI3Kα inhibitors for the treatment of different cancers (2021 - 2025)

INTRODUCTION: Oncogenic PIK3CA mutations drive numerous solid tumors, rendering PI3Kα a key therapeutic target. However, conventional ATP-competitive inhibitors are severely limited by dose-limiting metabolic toxicities caused by wild-type PI3Kα inhibition. To circumvent these limitations, the drug discovery landscape is rapidly shifting toward mutant-selective allosteric inhibitors designed to spare physiological signaling and expand the therapeutic window. AREAS COVERED: Utilizing the Cortellis Drug Discovery Intelligence (CDDI) database, this review evaluates patents of PI3Kα mutant-selective inhibitors disclosed between 2021 and 2025. The analysis focuses on structural features, pharmacological profiles, and medicinal chemistry strategies employed to achieve high selectivity for oncogenic mutants over the wild-type enzyme. Specifically, we examine the binding modes across two distinct allosteric domains: an H1047R-specific pocket (exemplified by Eli Lilly's inhibitors) and a pan-mutant cryptic site (engaged by RLY-2608 and STX-478). EXPERT OPINION: Mutant-selective allosteric inhibitors achieve selectivity by targeting mutant residues or exploiting unique protein conformational dynamics. The rapidly diversifying patent landscape provides broader opportunities for the discovery of superior inhibitors. Furthermore, development of allosteric inhibitor based PROTACs is discussed as a promising frontier for enhancing therapeutic precision. Ultimately, deeper understanding of evolving resistance mechanisms provides the design principles required to develop next-generation PI3Kα therapeutics capable of overcoming clinical resistance.